“…Moreover, many lead and drug candidates containing the N -(hetero)aryl cyclopropylamine moiety have been recently designed and synthesized, including potent Takeda G-protein-coupled receptor 5 (TGR5) agonists, an orally active and nonsteroidal farnesoid X receptor (FXR) antagonist, a topoisomerase inhibitor, and a modulator of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (Figure A). (ii) N -(Hetero)aryl cyclopropylamines are building blocks or key intermediates to access various novel ring systems in organic synthesis, e.g., the photocycloadditions of N -(hetero)aryl cyclopropylamines to alkenes, alkynes, or bicyclo[1,1,0]butanes to design various molecular skeletons (Figure B). − Hence, the development of effective methods for preparing N -(hetero)aryl cyclopropylamines is necessary and many endeavors have been made regarding this for decades.…”